Paper Details

  1. Home
  2. Paper Details

Acyclovir for the prevention of recurrent herpes simplex virus eye disease. Herpetic Eye Disease Study Group.

Author:

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

This study found that 12 months of treatment with acyclovir reduces the rate of recurrent ocular HSV disease and orofacial HSV disease in patients with a history of ocular HSV disease. The study suggests that long-term antiviral prophylaxis is most important for patients with a history of HSV stromal keratitis.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Long-term treatment with antiviral agents has been shown to prevent recurrences of genital and orofacial herpes simplex virus (HSV) disease, but it is uncertain whether prophylactic treatment can prevent recurrences of ocular HSV disease. METHODS: We randomly assigned 703 immunocompeten...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1056/NEJM199807303390503

データ提供：米国国立医学図書館（NLM）

Acyclovir: A Potential Solution for Recurrent Herpes Simplex Virus Eye Disease

Herpes simplex virus (HSV) eye disease, like a persistent desert mirage, can cause recurrent infections that can lead to vision loss. This research delves into the potential benefits of long-term acyclovir treatment in preventing recurrences of ocular HSV disease. The researchers conducted a randomized study comparing the effectiveness of acyclovir with placebo in patients with a history of ocular HSV infection. Their findings could provide valuable insights into the long-term management of this condition and its impact on visual health.

Acyclovir: A Potential Pathway to Preventing Recurrences

This research suggests that acyclovir can effectively reduce the rate of recurrent ocular HSV disease, particularly in individuals with a history of stromal keratitis, a serious form of HSV eye disease. These findings highlight the potential benefits of long-term acyclovir treatment in preventing vision loss and improving the quality of life for individuals with recurrent ocular HSV disease.

Herpes Simplex Virus (HSV) Eye Disease: Managing the Recurrences

Like a camel facing the challenges of a vast desert, individuals with recurrent ocular HSV disease can find relief in the appropriate management strategies. This research highlights the potential benefits of long-term acyclovir treatment in preventing recurrences. Consult with an ophthalmologist or healthcare professional to discuss the most effective treatment options for your individual situation and to ensure proper management of this condition.

Dr.Camel's Conclusion

This research highlights the potential benefits of long-term acyclovir treatment in preventing recurrences of ocular HSV disease, particularly in individuals with a history of stromal keratitis. The study underscores the importance of long-term antiviral prophylaxis in managing this condition and protecting visual health.

Date :
  1. Date Completed 1998-08-04
  2. Date Revised 2014-11-20
Further Info :

Pubmed ID

9696640

DOI: Digital Object Identifier

10.1056/NEJM199807303390503

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.